In this week's episode of Tuning In to the C-Suite podcast, Briana Contreras of MHE chatted with Daniel Drake, president and CEO of Trinity Health PACE, or Programs of All-Inclusive Care for the Elderly. Dan and Briana discussed the specifics of how PACE has grown in recent years, the outlook for these programs in the future and how PACE is benefitting older patients’ wellbeing and their healthcare costs.
Black HCM patients were more likely than White HCM patients to have mid-ventricular obstruction, according to recently reported findings.
Three experts say that pulmonary rehabilitation programs don’t necessarily result in improved lung function but are associated with improved physical and other sorts of functioning. Less than 5% of those who might benefit from pulmonary rehabilitation services received them.
People over the age 65 and those at high risk of severe COVID-19, including health care workers and those with occupational exposure, are eligible for the booster.
The next step is for the CDC's Advisory Committee on Immunization Practices to make a decision on whether to add a COVID-19 booster to its recommendations
Dr. Reddy’s has also launched a generic of Librax. Recent generic approvals include clindamycin phosphate foam and sodium acetate.
Copays and formulary tiers involve financial incentives to use certain drugs. But is Cigna’s offer of a $500 debit card in a different category?
Exact Sciences test that uses DNA methylation biomarkers is more sensitive than alpha-fetoprotein.
A recent City of Hope study claims a therapy that combines a drug that disrupts DNA repair with chemotherapy cisplatin and gemcitabine does not prolong progression-free survival for patients with urothelial cancer.
The Association for Accessible Medicines said biosimilar drugs saved $7.9 billion in 2020, more than tripling the $2.5 billion saved in 2019.
Research has linked many drugs to QT prolongation and decision support tools could alert clinicians to the risk and guide prescribing decisions to safer alternatives.
A recent study reveals longstanding innovation operation issues create a deep-seated risk to corporate growth performance.
The drug won't be available till next year but is expected to dent sales of Roche's blockbuster for age-related macular degeneration and other eye diseases.
Medical decision-making is challenging given the quantity of data and volume of evidence that exists. To overcome traditional barriers and deliver on the full promise of clinical decision support, practices should consider cloud-based composable platforms that bring leverage advancements in interoperability.
The organization expands existing initiatives to address systemic inequities with long-term, collaborative focus on community-based programs for serious chronic illness patients.
While there was a noticeable surge in telehealth usage during the global pandemic, broadband coverage has only increased by about 10%.
Advisory panel endorses Pfizer vaccine booster for some, Brukinsa gets third indication, oral migraine med makes headway and other FDA-related news this week.
Committee's two votes are only recommendations but a narrower booster emergency use authorization now seems likely.
The specialty drug spend and data flow and connectivity were among the themes of the presentations given at the hybrid conference this week in Orlando, Florida.
Tezepelumab, which is being currently reviewed by the FDA, provides small improvements in daily symptoms and quality of life but is only modestly cost-effectiveness at the anticipated price, according to the cost-effectiveness group's calculations.
Artificial intelligence is improving healthcare methods and insights. But when used incorrectly, AI is rife with pitfalls.
An Ibrance-Jakafi combination shows promise in a mouse model of myelofibrosis.
States are putting caps on prices, and Semglee, the first interchangeable biosimilar in the United States, may exert some downward pressure.
But CVS, Walgreens and Walmart differ in how they are setting up in-store health clinics.
The new company has developed an app and platform that guides cancer survivors through the experience of dealing with disease.
CVS’ Joshua Fredell, Pharm.D., and Tierra Ford, Pharm.D., described how an integrated, proactive approach can engage members and rein in costs.
Paula Bickley and Ashleigh Burdette of Biologics by McKesson described a program that identifies 1 in 3 patients as being at risk of nonadherence and then provides support to keep them on track and identify side effects and other problems early.
Confidio VP Thatcher Sloan described how applying formulary and utilization management effectiveness calculations to drug costs managed by PBMs may paint a truer picture of their economic value to their clients.
WellDyne executives David Skomo, RPh, and Nick Page told PBMI Annual Conference attendees that matching communication channels and messages with patient preference is the way to engage patients and increase adherence.
Abarca’s Javier Gonzalez discussed the advantage of health plans insourcing PBM services in an à la carte fashion.
